Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

CHICAGO, Oct. 9, 2020 /PRNewswire/ -- According to the new market research report "Cartilage Repair/ Cartilage Regeneration Market by Treatment modalities (Cell based Type (Chondrocyte Transplantation, Growth Factor), Non-Cell (Tissue Scaffolds)), Application (Hyaline), End User (ASCs, Clinic), Site (Knee) - Global Forecast to 2025", published by MarketsandMarkets, the Cartilage Repair/ Cartilage Regeneration Marketis projected to reach USD 1,603 million by 2025 from USD 787 million in 2020, at a CAGR of 15.3% during the forecast period.

Browse in-depth TOC on "Cartilage Repair/ Cartilage Regeneration Market"

144 Tables 41 Figures 157 Pages

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37493272

The growth of this market is primarily driven by the increasing incidence of osteoarthritis and increasing funding and investments for research in this field.

The cell-based segment accounted for the largest share of the treatment modality segment in the market in 2019.

Based on the treatment modality, the cartilage repair market is segmented into cell-based and non-cell-based approaches. The non-cell-based segment is divided into tissue scaffolds and cell-free composites. In 2019, the cell-based segment accounted for the largest share of the cartilage regeneration market. The large share of this segment can be attributed to technological advancements in stem cell-based therapies for cartilage repair and chondrocyte implantation products

The hospitals segment accounted for the largest share of the end user segment in the cartilage repair market in 2019.

Based on end users, the cartilage regeneration market is segmented into hospitals and ambulatory surgery centers (ASCs) and clinics. The hospitals segment accounted for the largest share of the market in 2019. This can be attributed to the large number of minimally invasive surgeries performed in hospitals and the growing number of hospitals in emerging economies.

Get 10% Customization on this Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=37493272

The Asia Pacific region is the fastest growing region of the cartilage repair and regeneration market in 2019.

The Asia Pacific region is estimated to grow at the highest CAGR in the cartilage repair market during the forecast period, this is mainly due to the rising geriatric population and the subsequent increase in the incidence of various disorders and injuries. Recent developments in tissue engineering and stem cell therapy will further fuel market growth.

Prominent players in the cartilage regeneration market are Smith & Nephew plc (UK), DePuy Synthes (US), Zimmer Biomet (US), CONMED Corporation (US), Stryker Corporation (US), and Vericel Corporation (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=37493272

Browse Related Reports:

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

https://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html

Arthroscopy Instruments Market by Type (Implants, Arthroscope, Visualization System, Surgical Shaver, RF Ablation, Fluid Management), Application (Knee, Hip, Shoulder), End User (Hospitals, Ambulatory Surgery Centers & Clinics) - Global Forecast to 2022

https://www.marketsandmarkets.com/Market-Reports/arthroscopy-instrument-market-238516643.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish Mehra MarketsandMarkets INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cartilage-repair-regeneration-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/cartilage-repair-regeneration.asp

SOURCE MarketsandMarkets

Read more:
Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Mission: a cure to cancer – Innovation Origins

Half of the total Dutch production value in Life Sciences & Health (around ten billion euros) is accounted for by the province of North Brabant, a recent report commissioned by the Brabant Development Fund BOM showed. Biotech, in particular, is growing rapidly: the number of new establishments has grown by 43% since 2014 and the number of jobs in this industry has doubled. Today, we take a closer look at one of the examples of this trend: Glycostem.

Roughly, there are three ways to fight cancer. Best known at the moment is chemotherapy, a chemical treatment that unfortunately kills good cells and bad cells at the same time. It has so many unwanted side effects that some experts argue that nowadays it wouldnt even receive approval as a treatment. Next, there are biological products. They are a step forwards, but not a cure. Biological immunotherapy can delay the end of therapy for cancer patients, which is already great. The third way could be the most interesting and promising one: cellular therapy. It contains the ultimate objective, curing cancer all the way. This is where Glycostem Therapeutics, based on Pivot Park Oss, comes in.

Glycostem is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, Glycostem claims. Due to their tightly regulated natural killing of cancer cells, they play an important role in the control and even cure of both solid and hematological malignancies, a statement on its website says. We had a conversation with CEO Troels Jordansen (56), a businessman with a history in a series of cellular therapy companies all over the world.

As a chairman, Troels Jordansen was already involved in Glycostem for a couple of years, when he was asked to take on the role as CEO four years ago. Although I knew the company quite well, this came a bit as a surprise to me. But I didnt need to think about the offer very long. There were two reasons why I really wanted to help move this company forward, and both were connected to the medical prospects: first, they had proven that cellular medicine could be moved to a level of cellular immunotherapy, and second, their way of using the human body as a source for raw material was something that really inspired me. And it still does.

Basically, Glycostem takes good cells to combat bad cells in the body. For now, the focus is on two specific cancers: Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). In pre-clinical trials, the company says it has shown remarkable results. The first clinical trial will start in October. Glycostem received approval to do the tests in four European countries. This is a huge step for us: we can now start treating patients. This is whats driving all of us: see patients live on, who otherwise may have died.

You can hardly imagine a world without cancer, but yes, we want to prove that treatment can become a reality. This is our mission.

From there, Jordansen wants to move to other cancers, including solid tumors. Cancer statistics are cruel. If we start making progress in AML and MM, we can start making progress in other cancers later. And in fifteen to twenty years time there will actually be hope for people who would otherwise have died. Marketing wise, this is also an important step for the company. The solid tumors represent a market that is ten times bigger than that of blood cancers. To give you an idea: US insurance companies now pay up to $450,000 per treatment.

In pre-clinical cell line tests, Jordansen says Glycostem has already shown that NK cells will have an effect on solid tumors as well. In early 2021, we will initiate clinical trials at UMC Amsterdam. We will be generating genetically manipulated NK-cells which will include a target. So if you have breast cancer, the NK-cell will go to the tumor, stay there, and step by step eat away this cancer. Can you imagine?

Jordansen is careful not to use the claim that this will ultimately cure cancer. Still, we have an opportunity to make a dent in the universe, to rephrase Steve Jobs. You can hardly imagine a world without cancer, but yes, we want to prove that treatment can become a reality. This is our mission.

The NK-cell will go to the tumor, stay there, and step by step eat away this cancer. Can you imagine?

In the past years, Glycostem was able to raise 35 million euros in equity, grants, and other deals. The company now employs 45 people, it owns a State-of-the-Art cleanroom and other fit-for-purpose facilities at the Pivot Park campus. Still, fulfilling the ultimate dream is not yet a done deal. We have to be realistic, our success still depends on factors which we cannot control completely. To name some, Glycostem could get strong competitors, from Asia or the US for example. At this point, we dont see them yet, but we will have to be aware of that. Also, new technology may someday be developed; a technology that might be cheaper, faster, or just more efficient. This will not happen overnight though, so were not very nervous about that. And finally, we might run out of money. If, for example, investors at a certain point decide to put their money in vaccines instead of cellular therapy, this could immediately affect us. Again, we dont have any signals that this is happening, but its something we will have to be aware of.

In the meantime, Glycostem is working towards the clinical trial initiation and, hopefully, the first real-life proof of a working therapy in the next 24 months or so. Our facilities in Pivot park help us reach those goals. We are part of a tradition and a community that understands what we are doing. Our employees learn from other companies, things come together. Because of our growth plans, we may someday need to move just outside the campus, but for now, this is the perfect place to be. It doesnt prevent Jordansen to look for collaborations elsewhere either: there are strong ties with the Amsterdam UMC, and Glycostem is also part of strong European networks. Teaming up means building your power together.

Troels Jordansen is convinced that every step Glycostem takes is bringing the world closer to the ultimate goal, a cure for cancer. Next milestone: the first results from the patients in the clinical tests that will start later this year. Rest assured that we will all be delighted and relieved the moment we get proof of patients surviving thanks to our therapy.

Glycostem is one of BOMs portfolio companies. This article is part of a series on the Brabant Life Sciences & Health ecosystem. More here.

Also read: A new cancer treatment

Originally posted here:
Mission: a cure to cancer - Innovation Origins

What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) – KQED

If reading through the statewide ballot propositions has made your head spin, you are in the right place! From Oct. 1 - 16, Bay Curious is exploring the 12 statewide ballot propositions in our Prop Fest series. This episode tackles Prop 14, the stem cell research bond.

Olivia Allen-Price [00:01:55] OK, so what exactly does this bond fund?

Danielle Venton [00:01:59] This would fund $5.5 billion in stem cell research and treatments in California. Some of the diseases that stem cell research is seeking to cure or treat include cancer, Alzheimer's disease, diabetes, spinal cord injuries, blindness, and even COVID-19. I spoke recently with a guy named Jake Javier. He supports this bond initiative because he knows firsthand how life changing stem cell research can be.

Jake Javier [00:02:25] I am in my last year at Cal Poly.

Danielle Venton [00:02:28] So, Jake grew up locally in Danville and was just graduating high school when he suffered a life altering injury.

Jake Javier [00:02:35] On the last day of high school, I drove in to a pool and hit my head on the bottom and broke my neck and was immediately paralyzed.

Danielle Venton [00:02:47] He says his injury was complete, with very little hope of recovery. But a doctor at Stanford reached out to Jake and his family and said, you can be part of this clinical trial where we, with a one time surgery, will inject stem cells into the damaged area and you may possibly see some benefits.

Danielle Venton [00:03:07] Now, Jake is still injured.

Jake Javier [00:03:09] I'm a quadriplegic. I use a wheelchair.

Danielle Venton [00:03:11] But he says after the surgery, he noticed more movement in his arms, in his hands.

Jake Javier [00:03:17] So, I mean, with my injury, I'm at a level where I would normally not have any function at all in my hands and very, very little function like in my triceps and things like that. Muscles that are really important for functionality and, you know, being able to get through day to day activities that could help me push myself around more, help me transfer in and out of my chair independently. And then also, I notice, you know, I got some some finger movement. It doesn't seem like much, but even that little movement has helped me so much with picking things up and things like that. So it was really, I was really blessed to see that happen.

Danielle Venton [00:03:51] So he doesn't know how much of his recovery is due to the stem cells. How much is natural, or how much is due to physical therapy. But today he's able to live independently, to go to college and he wants to pursue a career in medicine. And he is a big believer in stem cell research, regenerative medicine, and is really hoping that California voters will support this proposition.

Olivia Allen-Price [00:04:20] Now, what exactly are stem cells and how do they work, I guess?

Danielle Venton [00:04:25] Yeah, stem cells are types of cells that can be turned into any type of specialized cell. Scientists have known about them since the eighteen hundreds, but it wasn't until the late 90s that researchers developed a method to derive them from human embryos and grow them in a laboratory. And then people really began to get excited about their potential for medicine. Now these cells came from unused embryos created for in vitro fertilization, and they were donated with informed consent. But many anti-abortion groups felt that using the cells were tantamount to taking a human life. So in 2001, then President George W. Bush banned federal funding for any research using newly created stem cell lines.

Olivia Allen-Price [00:05:09] OK. And how does that get us now to bonds in California?

Danielle Venton [00:05:13] Well, Californians wanted to circumvent these federal restrictions, and in 2004 voted for a bond that gave the state $3 billion to create a research agency called the California Institute of Regenerative Medicine, or CIRM. There was a lot of public support for it. And it just felt like these wonderful cures could be right around the corner. Celebrities like Michael J. Fox appeared in TV commercials.

Michael J. Fox TV commercial [00:05:36] My most important role lately is as an advocate for patients, and for finding new cures for diseases. That's why I'm asking you to vote yes on Proposition 71, Stem Cell Research Initiative.

Danielle Venton [00:05:48] And the money for that research, that $3 billion, has now run out. And to continue their work, the stem cell advocacy group, Americans for Cures, is asking voters for more money.

Olivia Allen-Price [00:06:00] So we're basically voting on whether we want to refill the stem cell research piggy bank here.

Danielle Venton [00:06:05] Yeah, exactly. Some question if the state can afford this at this time when budgets are going to be so tight. Others have been disappointed by the slow pace of cures coming out of the field. Now, there are people who credit this research, such as Jake, with improving or restoring their health or the health of their loved ones. Or maybe they hope that one day it will, and they would balk at the idea that this is not worthy research. They point to achievements that the agency has funded. That includes effectively a cure for bubble baby disease. This is when someone is born without a functioning immune system. That mutation can now be corrected with genetically modified stem cells. And recently, just within the last year or so, the FDA approved two new treatments for blood cancer, developed with CIRM support. These achievements are what the agency points to when they're criticized for not having accomplished more. And they say the process of scientific discovery is long and unpredictable.

Olivia Allen-Price [00:07:04] Now, wasn't that Bush-era ban on stem cell research that you were talking about earlier wasn't that overturned?

Danielle Venton [00:07:11] Yes, that was overturned by President Obama. However, there are current members of Congress who are lobbying President Trump to ban the research again. And if that happens, then California would be the only major player in stemcell research once again in the United States.

Olivia Allen-Price [00:07:30] All right, so who is supporting Prop 14?

Danielle Venton [00:07:32] Governor Gavin Newsom, for one. Many patient advocacy organizations and medical and research institutions, including the California Board of Regents. These people don't want to see the pace of this research slow. They want it to accelerate. The political action committee supporting this proposition is reporting more than six million dollars in contributions.

Olivia Allen-Price [00:07:53] All right. And what about the opposition? Who's against it?

Danielle Venton [00:07:55] Well, so far, there's no organized, funded opposition. There have been several newspaper editorials coming out against it, including locally, the Mercury News and the Santa Rosa Press Democrat. They basically say state bonds aren't the way to fund research and the situation isn't like it was in 2004 and that the institute should now seek other sources of funding and move forward as a nonprofit.

Olivia Allen-Price [00:08:19] All right, Danielle. Well, thanks, as always for your help.

Danielle Venton [00:08:21] My pleasure. Thanks.

Olivia Allen-Price [00:08:28] In a nutshell, a vote yes on Proposition 14 says you think Californians should give $5.5 billion to the state's stem cell research institute. That money will be raised by selling bonds, which the state would pay back, with interest, out of the general fund over the next 30 years. A vote no means you think we shouldn't spend public money on this research.

Olivia Allen-Price [00:08:54] That's it on Proposition 14. We'll be back tomorrow with an episode on Prop 15. And oh, it is a doozy. Commercial property tax! A partial rollback of one of California's most controversial propositions! It's going to be fire. In the meantime, you can find more of KQED election coverage at KQED.org/elections. Two reminders on the way out: October 19th is the last day to register to vote and mail in ballots must be postmarked on or before November 3rd.

Olivia Allen-Price [00:09:28] Bay Curious is made in San Francisco at member supported KQED. I'm Olivia Allen-Price. See you tomorrow.

See the original post:
What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED

SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy – MIT News

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRFs initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.

SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.

Singapores well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing capabilities. We are excited to collaborate with our partners in Singapore, bringing together an interdisciplinary group of experts from MIT and Singapore, for new research areas at SMART. In addition to our existing research on our three flagship projects, we hope to develop breakthroughs in manufacturing other cell therapy platforms that will enable better medical treatments and outcomes for society, says Krystyn Van Vliet, co-lead principal investigator at SMART CAMP, professor of materials science and engineering, and associate provost at MIT.

Understanding glaucoma progression for better-targeted treatments

Hosted by SMART CAMP, the first research project, Retinal Analytics via Machine learning aiding Physics (RAMP), brings together an interdisciplinary group of ophthalmologists, data scientists, and optical scientists from SMART, Singapore Eye Research Institute (SERI), Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, MIT, and National University of Singapore (NUS). The team will seek to establish first principles-founded and statistically confident models of glaucoma progression in patients. Through retinal biomechanics, the models will enable rapid and reliable forecast of the rate and trajectory of glaucoma progression, leading to better-targeted treatments.

Glaucoma, an eye condition often caused by stress-induced damage over time at the optic nerve head, accounts for 5.1 million of the estimated 38 million blind in the world and 40 percent of blindness in Singapore. Currently, health practitioners face challenges forecasting glaucoma progression and its treatment strategies due to the lack of research and technology that accurately establish the relationship between its properties, such as the elasticity of the retina and optic nerve heads, blood flow, intraocular pressure and, ultimately, damage to the optic nerve head.

The research is co-led by George Barbastathis, principal investigator at SMART CAMP and professor of mechanical engineering at MIT, and Aung Tin, executive director at SERI and professor at the Department of Ophthalmology at NUS. The team includes CAMP principal investigators Nicholas Fang, also a professor of mechanical engineering at MIT; Lisa Tucker-Kellogg, assistant professor with the Cancer and Stem Biology program at Duke-NUS; and Hanry Yu, professor of physiology with the Yong Loo Lin School of Medicine, NUS and CAMPs co-lead principal investigator.

We look forward to leveraging the ideas fostered in SMART CAMP to build data analytics and optical imaging capabilities for this pressing medical challenge of glaucoma prediction, says Barbastathis.

Cell transplantation to treat irreparable spinal cord injury

Engineering Scaffold-Mediated Neural Cell Therapy for Spinal Cord Injury Treatment (ScaNCellS), the second research project, gathers an interdisciplinary group of engineers, cell biologists, and clinician scientists from SMART, Nanyang Technological University (NTU), NUS, IMCB A*STAR, A*STAR, French National Centre for Scientific Research (CNRS), the University of Cambridge, and MIT. The team will seek to design a combined scaffold and neural cell implantation therapy for spinal cord injury treatment that is safe, efficacious, and reproducible, paving the way forward for similar neural cell therapies for other neurological disorders. The project, an intersection of engineering and health, will achieve its goals through an enhanced biological understanding of the regeneration process of nerve tissue and optimized engineering methods to prepare cells and biomaterials for treatment.

Spinal cord injury (SCI), affecting between 250,000 and 500,000 people yearly, is expected to incur higher societal costs as compared to other common conditions such as dementia, multiple sclerosis, and cerebral palsy. SCI can lead to temporary or permanent changes in spinal cord function, including numbness or paralysis. Currently, even with the best possible treatment, the injury generally results in some incurable impairment.

The research is co-led by Chew Sing Yian, principal investigator at SMART CAMP and associate professor of the School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine at NTU, and Laurent David, professor at University of Lyon (France) and leader of the Polymers for Life Sciences group at CNRS Polymer Engineering Laboratory. The team includes CAMP principal investigators Ai Ye from Singapore University of Technology and Design; Jongyoon Han and Zhao Xuanhe, both professors at MIT; as well as Shi-Yan Ng and Jonathan Loh from Institute of Molecular and Cell Biology, A*STAR.

Chew says, Our earlier SMART and NTU scientific collaborations on progenitor cells in the central nervous system are now being extended to cell therapy translation. This helps us address SCI in a new way, and connect to the methods of quality analysis for cells developed in SMART CAMP.

Cell therapy, one of the fastest-growing areas of research, will provide patients with access to more options that will prevent and treat illnesses, some of which are currently incurable. Glaucoma and spinal cord injuries affect many. Our research will seek to plug current gaps and deliver valuable impact to cell therapy research and medical treatments for both conditions. With a good foundation to work on, we will be able to pave the way for future exciting research for further breakthroughs that will benefit the health-care industry and society, says Hanry Yu, co-lead principal investigator at SMART CAMP, professor of physiology with the Yong Loo Lin School of Medicine, NUS, and group leader of the Institute of Bioengineering and Nanotechnology at A*STAR.

The grants for both projects will commence on Oct. 1, with RAMP expected to run until Sept. 30, 2022, and ScaNCellS expected to run until Sept. 30, 2023.

SMART was. established by the MIT in partnership with the NRF in 2007. SMART is the first entity in the CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Centre and five interdisciplinary research groups (IRGs): Antimicrobial Resistance, CAMP, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

CAMP is a SMART IRG launched in June 2019. It focuses on better ways to produce living cells as medicine, or cellular therapies, to provide more patients access to promising and approved therapies. The investigators at CAMP address two key bottlenecks facing the production of a range of potential cell therapies: critical quality attributes (CQA) and process analytic technologies (PAT). Leveraging deep collaborations within Singapore and MIT in the United States, CAMP invents and demonstrates CQA/PAT capabilities from stem to immune cells. Its work addresses ailments ranging from cancer to tissue degeneration, targeting adherent and suspended cells, with and without genetic engineering.

CAMP is the R&D core of a comprehensive national effort on cell therapy manufacturing in Singapore.

Read more:
SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy - MIT News

Abu Dhabi Stem Cells Centre collaborating with Israeli firm for COVID-19 therapies – Gulf News

A medical staff member carries a swab sample for testing at a screening centre in Abu Dhabi.

Abu Dhabi: UAE's Abu Dhabi Stem Cells Centre (ADSCC) is collaborating with Israeli regenerative medicine company, Pluristem, to advance COVID-19 therapies.

In a statement, ADSCC said it was working to administer Pluristem developed PLX cells via a nebuliser to COVID-19 patients. The collaboration will allow ADSCC to expand its stem cell therapy options with the novel PLX cells, while also enabling Pluristem to leverage the ADSCCs nebuliser administration experience to develop a new treatment delivery model for PLX cells.

ADSCC has reported effective usage of nebulisers to treat patients suffering from COVID-19 infection, with stem cells sourced from the patients own blood.

Further discussions are also ongoing to treat chronic Graft Versus Host Disease (cGvHD) a life-threatening immune response to the donors stem cells against the host (patient).

Both projects follow a recently-signed agreement between ADSCC and Pluristem to harness the power of regenerative medicine.

Visit link:
Abu Dhabi Stem Cells Centre collaborating with Israeli firm for COVID-19 therapies - Gulf News

Majority of Respondents Support Chimeric Animal Research: Survey – The Scientist

Human-animal chimeric embryosorganisms created using cells from two or more specieshave the potential to change how researchers study disease and generate organs and tissues for human transplants. One day, scientists have proposed, it may be possible for someone with, say, pancreatic cancer to have their stem cells injected into a modified swine embryo lacking its own pancreas so it can grow the human organ for donation.

Already, human-animal chimeric embryos (HACEs) have been created using human cells injected into pigs, sheep, mice, rats, and monkeys, although none in the US have been brought to term. In fact, their very existence is ethically contentious. What happens, for example, if scientists were to grow a human brain in an animal, blurring the line between species?

In response to ethical, social, and legal concerns, the National Institutes of Health (NIH) issued a moratorium on funding for HACE research in 2015 pending the development of a new set of regulatory guidelines. While research continues in other countriesand even in the US, through collaborations with foreign researchers and private fundingthe NIH has yet to reverse its decision, despite previous announcements that it would do so.

To gauge the American publics support for HACE research, Francis Shen, a professor of law at the University of Minnesota, recreated two recent surveys carried out in Japan, where many of the worlds HACE studies are done. In those surveys, Shens colleagues found that the majority of the Japanese public supported the use of HACEs, although their feelings varied depending on the type of organ or tissue being grown. We thought, Boy, itd be really interesting to see if the American public thinks about things the same way, Shen tells The Scientist.

Shens team directly translated the Japanese surveys into English, asking 430 participants to rate their support for each of the three steps involved in producing an organ using HACE technology: the insertion of human stem cells into an animal embryo, the transplanting of the embryo into a surrogate, and the harvesting of the resulting organ for use in a human. As before, they gauged peoples reactions to organ and tissue types, including skin, liver, blood, heart, brain, and gametes.

The Scientistspoke with Shen about the results of the US study, published today (October 1) in Stem Cell Reports.

University of Minnesota Law School

Francis Shen:Organ transplantation is a major goal, and that would be a major breakthrough. When I describe [HACEs] to . . . colleagues who maybe havent heard of them before, I talk about organ transplantation. And they understand that, yes, if you grow an organ from your own cells, it makes intuitive sense that your body might be more receptive.

I think there are also a large number of applications that fall broadly under regenerative medicine. One is to better understand the mechanisms of disease and organ function. Theres basic science advances to be achieved there. And then there are applied clinical advances and improvements in treatment across a wide range of diseases and disorders. We can develop better interventions, pharmacological and otherwise. The techniques are not just about improving organ donation. There are also a number of ways, through both basic and applied science, this work can really improve our knowledge and therefore response to any number of diseases and disorders.

FS: One of the main findings was that there seems to be very broad support, even broader than in the Japanese public, for the different steps of HACE research. Support was 59 percent, so a strong majority, support all three steps, including the returning of the organ into a human.

Second was that there are some differences across subgroups in the public. One thing that we thought was interesting is that, although lower, in some instances the support of those who are politically conservative was still quite strong . . . suggesting that this type of stem cell researchusing [induced pluripotent stem] cells and not embryonic stem cells harvested from a fetusperhaps could be more politically palatable.

FS:[People are] more accepting of using HACEs to grow things like livers and skin than sperm, eggs, or brains, and I think it gets to humanization. Its speculation, but I think its informed speculation based on other ethical scholarship and work that has been done. A liver is kind of a liver, it doesnt seem to have too many special properties, but the sperm and the egg and the brain, those are part and parcel of a person. So it feels much more ethically concerning to grow a person in a pig, as opposed to growing just some constituent part of a person.

Someone has a heart transplant or a liver transplant, and it just kind of seems to make more sense. I think theres a cultural acceptance and understanding thats easier to analogize to.

There are a series of ethical concerns, and we tried pretty hard in the paper to emphasize that. They include animal welfare, human dignity, and then the potential for the neurological humanization of chimeric animals.

I think addressing them is tremendously important. Although the NIH has a moratorium presently, it doesnt mean this type of research isnt going to happen. If the NIH doesnt fund it with these ethical guidelines in place, it could be funded and produced elsewhere outside of NIH purview. So not only is there an opportunity to set the ethics frameworks here, theres almost an imperative to do so.

The bottom line for me is that the ethics and the laws and regulation should go hand in hand with the development of the research. And to do that productively means we need to get together and work through these complicated issues. What our study suggests is that the American public would like us to do that.

Editors note: The interview was edited for brevity.

Visit link:
Majority of Respondents Support Chimeric Animal Research: Survey - The Scientist

Election 2020: Prop. 14 and stem cell research funding – KCBX

In November, California voters will be deciding on a dozen statewide ballot measures. One is about funding stem cell research through bonds, Proposition 14.

Just one day before his high school graduation, Cal Poly football recruit Jake Javier dove into a friends swimming pool and hit his head on the bottom, leaving him paralyzed from the chest down.

The next thing I knew I was being told Im a quadriplegic," Javier said. "I broke my neck at the C6 level.

Javiers plans to play football in collegenow gone. He was told he was never going to walk again.

I really didnt have time to panic, or feel sorry for myself," Javier said. "Immediately it was survival mode for the next couple weeks, I was on a ventilator [and] couldnt breathe, and then from there it was starting my rehab.

Less than a week post-injury, he got a call from a Stanford doctor who said the teen would make a great candidate for a stem cell trial they were conducting.

They were very clear about the possible outcomes of it," Javier said. "They were like yeah it could potentially help you we dont know how much, it could potentially negatively affect you and hurt your function.'"

Javier decided even if it wouldnt help him, the research could help others, so he became a part of the trial. Doctors injected stem cells in him in a one-time surgery, then monitored and tested Javier's progress for months. He says he had a positive outcome.

I regained more strength in my arms than what was expected, I have a little bit of finger movement that isnt a whole lot, but it's functional," Javier said. "Honestly Im really glad I went through with it because I have no idea where Id be without it.

This election, California voters will decide whether to pay for more stem cell research like this via Proposition 14. It continues programs approved by voters in 2004.

A UC San Diego professor of cellular and molecular medicine, Lawrence Goldstein, says it will fund research and therapy for Alzheimers, Parkinsons, cancer, and other brain and central nervous system diseases and conditions.

It would authorize five and a half billion dollars," Goldstein said. "In what are called general obligation funds that would then be used to fund stem cell research in medicine.

Opponents argue with California facing a huge budget deficit due to the pandemic, Prop. 14 would take billions away from more pressing needs like housing and education. And that back in 2004, state voters approved funding because the federal government wasnt supporting stem cell research, but thats no longer the case.

See the original post:
Election 2020: Prop. 14 and stem cell research funding - KCBX

Hair Regeneration Therapy Company Stemson Therapeutics Raises $7.5 Million – Pulse 2.0

Stemson Therapeutics announced that it has raised a $7.5 million seed round of funding led by Allergan Aesthetics (an AbbVie Company) and impact investor Fortunis Capital to advance the development of Stemsons therapeutic solution to cure hair loss. This funding round enables Stemson to advance its goal of restoring human hair growth with a novel approach using the patients own cells to generate new hair follicles.

Allergan Aesthetics is known as a world-leading medical aesthetics company. And Fortunis Capital is committed to continuing support of Stemsons regenerative cell therapy to treat hair loss through its new Impact Fund which intends to invest in companies that offer significant social or environmental benefit.

The seed funding round supports the preclinical development of Stemsons Induced Pluripotent Stem Cell (iPSC) based technology which is capable of producing the cell types required to initiate hair follicle growth. And globally, hundreds of millions of men and women suffer from various forms of hair loss and no solution today is capable of generating a new supply of follicles for patients in need.

The initial seed financing round enables Stemson to expand its management team and R&D resources while recent approval of a foundational patent provides stability surrounding the companys efforts to develop its radical solution for hair growth. The additions of Meghan Samberg, Ph.D. as Vice President of R&D and Preclinical Development and Cenk Sumen, Ph.D. as Chief Technology Officer complement the work of Stemsons cofounder and Chief Scientific Officer Dr. Alexey Terskikh and the R&D team.

Stemson received approval in the United States of its cornerstone Human Induced Pluripotent Stem Cell (iPSC) method patent licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. And the patent covers a novel process developed by Dr. Terskikh to differentiate iPSC into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. The patent secures foundational methods using iPSC cell therapy to grow hair.

KEY QUOTES:

Stemsons novel cell therapy approach to treat hair loss has game-changing potential. Their experienced management team is poised to elevate its proprietary regenerative cell therapy method as it begins the next phase of its preclinical program. Fortunis Capital is committed to supporting companies that are creating innovative solutions with worldwide social or environmental benefit, and we believe that Stemson has the team, technology and the tools in place to develop a therapy capable of solving the hair loss problem for millions of people in need.

Sir Andrew Ross, Director of Investments at Fortunis Capital

Allergan Aesthetics research and development efforts are focused on products and technologies that drive the advancement of aesthetics medicine. Hair loss is a significant unmet medical need for millions of men and women, and Stemson Therapeutics efforts to develop novel methods to regrow hair is an opportunity to make a difference in this area.

Yehia Hashad, M.D. Senior Vice President, Research and Development, Allergan Aesthetics.

Stemson has established the biological and technical building blocks which are needed to solve the problem of hair loss. A truly curative solution is now feasible, and we have built a world-class team to deliver a therapy for the millions of hair loss sufferers across the world. We are grateful for support from Allergan Aesthetics and Fortunis Capital, and we look forward to expanding our base of investors as we move toward our first human clinical trial.

Geoff Hamilton, cofounder and chief executive officer of Stemson Therapeutics

Excerpt from:
Hair Regeneration Therapy Company Stemson Therapeutics Raises $7.5 Million - Pulse 2.0

Intestinal Organoid Built That Looks and Functions Like Real Tissue – Genetic Engineering & Biotechnology News

Organoids, which originate from stem cells, are a tool with great potential for modeling tissue and disease biology. The idea is to build miniature tissues and organs that accurately resemble and behave like their real counterparts. But there have been limitations to their development. A new study has taken organoids a step further by inducing intestinal stem cells to form tube-shaped epithelia with an accessible lumen and a similar spatial arrangement of crypt- and villus-like domains to that in vivo. These mini-intestines also retain key physiological hallmarks of the intestine and have a notable capacity to regenerate.

The work is published in Nature in the paper titled, Homeostatic mini-intestines through scaffold-guided organoid morphogenesis.

Organoids could complement animal testing by providing healthy or diseased human tissues, expediting the lengthy journey from lab to clinical trial. Beyond that, organoid technology may hold promise, in the long-term, to replace damaged tissues or even organs in the future. For example, by taking stem cells from a patient and growing them into a new liver, heart, kidney, or lung.

So far, established methods of making organoids come with considerable drawbacks: stem cells develop uncontrollably into circular and closed tissues that have a short lifespan, as well as non-physiological size and shape, all of which result in overall anatomical and/or physiological inconsistency with real-life organs.

Now, scientists from the group led by Matthias Ltolf, PhD, professor at EPFLs Institute of Bioengineering, have found a way to guide stem cells to form an intestinal organoid that looks and functions just like real tissue. The method exploits the ability of stem cells to grow and organize themselves along a tube-shaped scaffold that mimics the surface of the native tissue, placed inside a microfluidic chip.

The researchers used a laser to sculpt the gut-shaped scaffold within a hydrogel, a soft mix of crosslinked proteins found in the guts extracellular matrix supporting the cells in the native tissue. Aside from being the substrate on which the stem cells could grow, the hydrogel thus also provides the form or geometry that would build the final intestinal tissue.

Once seeded in the gut-like scaffold, within hours, the stem cells spread across the scaffold, forming a continuous layer of cells with its characteristic crypt structures and villus-like domains. Then came a surprising result: the scientists found that the stem cells arranged themselves in order to form a functional tiny gut.

It looks like the geometry of the hydrogel scaffold, with its crypt-shaped cavities, directly influences the behavior of the stem cells so that they are maintained in the cavities and differentiate in the areas outside, just like in the native tissue, said Ltolf. The stem cells didnt just adapt to the shape of the scaffold, they produced all the key differentiated cell types found in the real gut, with some rare and specialized cell types normally not found in organoids.

Intestinal tissues are known for the highest cell turnover rates in the body, resulting in a massive amount of shed dead cells accumulating in the lumen of the classical organoids that grow as closed spheres and require weekly breaking down into small fragments to maintain them in culture. The introduction of a microfluidic system allowed us to efficiently perfuse these mini-guts and establish a long-lived homeostatic organoid system in which cell birth and death are balanced, said Mike Nikolaev, a graduate student and the first author of the paper.

The researchers demonstrated that these miniature intestines share many functional features with their in vivo counterparts. For example, they can regenerate after massive tissue damage and they can be used to model inflammatory processes or host-microbe interactions in a way not previously possible with any other tissue model grown in the laboratory.

In addition, this approach is broadly applicable for the growth of miniature tissues from stem cells derived from other organs such as the lung, liver, or pancreas, and from biopsies of human patients. Our work, explained Ltolf, shows that tissue engineering can be used to control organoid development and build next-gen organoids with high physiological relevance, opening up exciting perspectives for disease modeling, drug discovery, diagnostics, and regenerative medicine.

Read this article:
Intestinal Organoid Built That Looks and Functions Like Real Tissue - Genetic Engineering & Biotechnology News

Regenerative Therapy by Dr. Roshni Patel on Better CT – Farmington, CT – Patch.com

This post was contributed by a community member. The views expressed here are the author's own.

When youre in pain, its important to find effective, long-lasting solutions that can provide short recovery periods. This is what regenerative medicine offers. Over the past decade, there has been a growing field of medicine that utilizes the bodys own healing capabilities using platelet-rich plasma and mesenchymal stem cells (MSCs). This growing field is labeled as regenerative medicine. Regenerative therapies focus on healing and help regrow damaged tissue naturally. Regenerative injection therapy is used to provide relief to musculoskeletal injuries that involve damage to ligaments, tendons, cartilage, joints, and discs.

Watch video of PRP:

PRP therapy on Better CT

PRP is safeas we are using what your body naturally produces, concentrating the desired critical components and transplanting them into the affected area for effective tissue regeneration and healing. There is no risk of rejection and very minimal overall procedural risk.

FDA regulations do not allow for the cloning of stem cells or growing them in a lab. Also, stem cells derived from fat cells are not approved by the FDA as it does not allow for manipulation. This leaves us to another rich stem cell source in our body which is bone marrow. Stem cells exist in our bodies and are rudimentary cells that can differentiate into other cells.

Think of bone marrow stem cells as the mother cell that is responsible for producing new blood cells. Bone marrow contains hundreds of growth factors and is often used for severe degenerative conditions or where PRP therapy may not be sufficient to provide the growth factors needed to provide relief.

Lastly, there are many offshoot therapies that use biologics derived from placental tissue or blood cord. These biologics are sometimes marketed as Stem cells but are not stem cells and contain zero viable cells. What they contain are growth factors that can also aid when combined with PRP or Stem Cells derived from your own body.

MSCs and PRPmay be used to target a number of conditions that could benefit from their healing and regenerative qualities. Especially when considering chronic pain, alternative solutions may be necessary if it has been difficult to find relief. Along with generalized joint pain, MSCs and PRPmay be used to target:

With so many options for joint pain out there, you may be wondering what benefits choosing stem cell therapy provides. Overall, because mesenchymal stem cell therapy utilizes biologic material harvested directly from the patients body, the general benefits include minimal risk, minimal recovery time, and minimal worry:

Avoid surgery and its many complications and risks: Stem cell therapy is a minimally invasive, non-surgical procedure.

Minimal post-procedural recovery time: One of the most time-consuming factors of any injury is not always the treatment itself, but actually the recovery time. With stem cell therapy, recovery time is minimal.

No risk of rejection: Due to using biologics extracted from the patient, there is no risk of rejection.

No communicable disease transmission: As the cells originate within your own body, there is no risk of spreading disease from or to another person.

If you are suffering from joint pain, back pain, or a debilitating condition like osteoarthritis, it is important to consider all of your available options. Our elite team of professionals can determine if you are the right candidate for MSCs. If youre interested in learning more, contact us today.

Excerpt from:
Regenerative Therapy by Dr. Roshni Patel on Better CT - Farmington, CT - Patch.com